What Causes Low Estrogen in Women?

Estrogen in this context usually means estradiol (E2), the dominant circulating estrogen in premenopausal women and the form measured on standard blood panels. It is distinct from estrone (E1, the dominant postmenopausal estrogen) and from synthetic ethinyl estradiol used in combined oral contraceptives. Hormone replacement therapy (HRT) for estrogen deficiency uses bioidentical estradiol, delivered orally, transdermally, or vaginally, and is a different clinical decision than contraceptive dosing. This article covers causes of hypoestrogenism, not dosing or product selection.

The direct answer, with its boundary

Low estradiol in a woman of reproductive age or beyond almost always traces back to one of two mechanisms: the ovaries have run out of functioning follicles (menopause, POI, surgical removal, radiation, or chemotherapy damage), or the brain has stopped sending the signal that drives the ovaries (hypothalamic suppression from energy deficit, stress, or excess exercise; or pituitary suppression from high prolactin or certain drugs). A follicle-stimulating hormone (FSH) level, read alongside estradiol, distinguishes the two patterns: high FSH with low estradiol points to ovarian failure, while low or low-normal FSH with low estradiol points to a central (hypothalamic or pituitary) cause. This single distinction, not the estradiol number by itself, is what should guide the next diagnostic step.

Why the ovarian-versus-central distinction matters

The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses. GnRH drives the pituitary to secrete FSH and luteinizing hormone (LH), which stimulate the ovarian follicles that produce estradiol. If the ovaries lose their follicle reserve, the pituitary senses low estradiol and raises FSH and LH in compensation, so the ovarian-failure pattern is low estradiol with high FSH/LH. If the hypothalamus itself is suppressed, FSH and LH stay low or low-normal even though estradiol is also low, because the signal to the ovary was never sent. This is the basis for distinguishing causes clinically, and it is standard endocrinology, not a page-specific claim.

Normal estradiol varies widely across the menstrual cycle: roughly 30 to 120 pg/mL in the follicular phase, a mid-cycle peak that can exceed 200 pg/mL, and a luteal-phase plateau in between. Postmenopausal estradiol is typically well below 20 pg/mL, and surgical menopause (removal of both ovaries) can drop estradiol into the single digits within days. These reference ranges vary somewhat by laboratory assay, and a single measurement should be interpreted against the specific lab's reference range rather than a universal cutoff.

Menopause: the most common cause

Natural menopause is defined clinically as 12 consecutive months without a menstrual period, reflecting depletion of the ovarian follicle pool that occurs gradually over decades. In the United States the median age at natural menopause is in the early 50s. The transition (perimenopause) that precedes it can last several years and is marked by an erratic rather than steady decline in estradiol, with some cycles producing near-normal levels and others producing menopausal-range troughs. This variability is why a single low estradiol reading during the 40s does not by itself confirm menopause; a pattern over time, along with FSH and symptoms, is more informative.

Vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (vaginal dryness, painful intercourse, urinary symptoms) are direct downstream effects of estrogen withdrawal and are common during and after the transition, though exact prevalence figures vary across studies and populations and should not be quoted as fixed percentages without checking the specific source population.

Premature ovarian insufficiency (POI)

POI describes ovarian function that becomes irregular or stops before age 40, distinguishing it from normally timed menopause. Working definitions generally require menstrual irregularity or absence for several months together with an elevated FSH confirmed on more than one occasion. Recognized underlying causes include:

• Chromosomal abnormalities, including Turner syndrome (45,X) and the FMR1 premutation associated with fragile X syndrome, which carries an increased lifetime risk of POI.
• Autoimmune oophoritis, sometimes occurring alongside autoimmune adrenal insufficiency; antibody testing can help identify this subgroup.
• Idiopathic POI, where no cause is found despite a full workup; this is the largest category in most case series.

Because POI means many additional years of estrogen deficiency compared with typical menopause, guideline bodies in reproductive endocrinology generally recommend hormone therapy be continued until at least the average natural age of menopause to protect bone and cardiovascular health, with the specific regimen individualized. Readers with a new POI diagnosis should verify current recommendations with a reproductive endocrinologist, since dosing and duration are individualized and not something this article can specify.

Hypothalamic amenorrhea: low estrogen from the brain down

Functional hypothalamic amenorrhea (HA) occurs when the hypothalamus reduces GnRH pulsatility in response to energy deficiency, psychological stress, or heavy exercise training, often in combination. Unlike menopause or POI, the ovaries in HA are structurally normal and contain follicles; FSH and LH are low or low-normal rather than elevated, and estradiol falls as a downstream consequence rather than an ovarian failure.

A comparative study of bone mineral density in women with functional hypothalamic amenorrhea against eumenorrheic controls and recently menopausal women found that the duration and mechanism of estrogen deficiency both matter for bone outcomes, reinforcing that HA is not a benign, purely reversible state if it persists untreated (source). This is a recent primary-literature finding and its full clinical implications, including whether bone effects fully reverse after recovery, require follow-up in the primary paper before being generalized to individual patients.

Clinical guidance for functional hypothalamic amenorrhea generally favors restoring adequate energy intake, moderating exercise load, and addressing psychological stress as the primary treatment, rather than covering the deficit with exogenous estrogen, because hormone therapy alone does not reliably normalize bone density or address the underlying energy imbalance. Estrogen therapy can still be appropriate if bone loss is already documented and the underlying trigger cannot be corrected quickly, but that decision should be made with an endocrinologist or a physician experienced in the RED-S (Relative Energy Deficiency in Sport) framework, not from a lab value alone.

Surgical menopause

Bilateral oophorectomy (removal of both ovaries) causes an abrupt, complete loss of ovarian estradiol production, generally within days, which tends to make surgical menopause more symptomatically severe than the gradual decline of natural menopause. Because the drop is sudden and, if it occurs before the natural age of menopause, prolongs the total duration of estrogen deficiency, most gynecologic guidance supports offering systemic estrogen therapy to women under the average age of natural menopause who undergo bilateral oophorectomy, unless there is a specific contraindication such as active hormone-sensitive cancer. Any claim about a specific mortality or health-outcome difference tied to a named cohort study should be checked against the primary publication rather than taken from a secondary summary, since this draft could not verify a specific citation for that figure.

Elevated prolactin (hyperprolactinemia)

Prolactin, secreted by the pituitary, suppresses GnRH pulsatility when chronically elevated, producing a central pattern of low estradiol with low or low-normal FSH/LH. Common causes include a prolactin-secreting pituitary tumor (prolactinoma), dopamine-blocking medications, hypothyroidism, and chronic kidney disease. Prolactinomas are typically treated first with a dopamine agonist (commonly cabergoline), which lowers prolactin and, in most responders, restores normal GnRH pulsatility and estradiol over weeks to a couple of months. Specific normalization rates and dosing differ by patient and should come from the prescribing physician rather than a general reference figure.

Medications that suppress estrogen

GnRH agonists (leuprolide, nafarelin, goserelin) are used for endometriosis, uterine fibroids, and in some prostate cancer and gender-affirming care protocols. Continuous, non-pulsatile exposure downregulates pituitary GnRH receptors, which suppresses FSH/LH and drops estradiol to postmenopausal levels within a few weeks, sometimes producing menopause-like symptoms as a known and expected drug effect. GnRH antagonists (elagolix, relugolix, cetrorelix, ganirelix) act faster and can produce similarly low estradiol within days. Add-back estrogen therapy during longer courses of GnRH agonist or antagonist treatment is a recognized strategy to offset bone loss and vasomotor symptoms, and is FDA-labeled for some of these regimens; the specific add-back protocol should come from the prescribing label and physician, not this article.

Aromatase inhibitors (anastrozole, letrozole, exemestane) block the peripheral conversion of androgens to estrogens and are FDA-approved for hormone-receptor-positive breast cancer, primarily in postmenopausal women. In postmenopausal patients they markedly suppress circulating estradiol. In premenopausal women, aromatase inhibition alone can trigger a reflex FSH rise that stimulates the ovary and partially overrides the drug, which is why aromatase inhibitor therapy in premenopausal breast cancer typically requires concurrent ovarian suppression with a GnRH agonist. This combination is a guideline-supported, oncologist-directed decision and is not something to adjust based on a general article.

Dopamine-blocking antipsychotics (risperidone, haloperidol, and some others) raise prolactin as a class effect, which can secondarily suppress estradiol through the mechanism described above. Not all antipsychotics carry the same prolactin risk, and switching or adjusting psychiatric medication for this reason should only be done in coordination with the prescribing psychiatrist, given the risk of destabilizing the underlying condition being treated.

Radiation, chemotherapy, and other medical causes

Pelvic radiation delivered directly to the ovaries and gonadotoxic chemotherapy (particularly alkylating agents such as cyclophosphamide) can cause permanent or temporary ovarian follicle loss, with risk rising with cumulative dose. Ovarian transposition before radiation, and in some protocols temporary GnRH agonist co-treatment during chemotherapy, are used as ovarian-protective strategies; effectiveness varies by regimen and should be discussed with the treating oncology team, since exact protection rates depend on the specific drugs, doses, and patient age.

Thyroid dysfunction (both hypothyroidism and hyperthyroidism) can disrupt the menstrual cycle and, in more severe hypothyroidism, raise prolactin; correcting the thyroid disorder is typically the first step, before considering separate estrogen therapy. Turner syndrome (45,X) is the most common chromosomal cause of ovarian failure and usually requires estrogen replacement timed to the expected age of puberty to support normal development and bone health, a decision made by pediatric or reproductive endocrinology. Advanced chronic kidney disease can also disrupt the hypothalamic-pituitary-ovarian axis through several overlapping mechanisms, including altered hormone clearance and secondary hyperprolactinemia.

Lifestyle factors

Very low body fat and inadequate caloric intake suppress the hypothalamic signal described above; this is the mechanism underlying hypothalamic amenorrhea in low-weight or heavily exercising women, not a separate cause. Chronic heavy alcohol use and smoking are both associated with disruption of estrogen metabolism and, in the case of smoking, with somewhat earlier menopause onset in population studies, though the size of that effect varies across cohorts. Very low-fat diets can reduce the cholesterol substrate available for steroid hormone synthesis, but this is a modest and reversible effect in most people rather than a primary cause of clinically significant hypoestrogenism, and should not be assumed to explain a low estradiol result without first ruling out the causes above.

What a diagnostic workup typically includes

• Serum estradiol (follicular phase if cycling, random if amenorrheic)
• FSH and LH, to distinguish an ovarian from a central cause
• Prolactin
• TSH (thyroid screening)
• Anti-Müllerian hormone (AMH), reflecting ovarian reserve
• Karyotype and FMR1 premutation testing if POI is confirmed before age 35
• Anti-21-hydroxylase antibodies if autoimmune oophoritis is suspected
• Pelvic ultrasound (antral follicle count)
• DEXA bone density scan if amenorrhea has persisted for several months or longer

A diagnosis of POI, or any unexplained hypoestrogenism in a woman under 40, warrants a clear, unhurried conversation with a physician about the diagnosis, its implications for fertility and bone health, and the treatment plan, not just a lab report. This is a widely endorsed principle in reproductive endocrinology, though the exact language of any specific guideline statement should be verified against the current published version before being quoted directly.

Evidence boundary: what is established, what is plausible, what is not

Established: Menopause, POI, surgical oophorectomy, hypothalamic suppression, hyperprolactinemia, several specific drug classes (GnRH agonists/antagonists, aromatase inhibitors), and gonadotoxic radiation or chemotherapy all lower estradiol through defined, well-described mechanisms. The FSH/LH pattern reliably distinguishes ovarian from central causes.

Plausible but not fully settled from the material reviewed here: The precise degree to which functional hypothalamic amenorrhea causes lasting bone loss versus fully reversible bone loss once energy balance is restored is still being actively studied, as reflected in recent comparative bone density research. Population-level estimates for symptom prevalence, exact hormone thresholds, and dose-response relationships cited in older secondary sources should be treated as approximate rather than exact until checked against the specific primary study.

Not established from this review: This article does not establish individualized dosing, specific product choices, or a mortality or safety comparison tied to any single named study, because the underlying citation for those figures could not be verified. A reader considering hormone therapy for any of these causes needs an individualized evaluation, not a number from a general article.

A decision framework: narrowing the cause before deciding what to do

Use this information to guide questions you might ask your healthcare provider, but it should not replace your own medical evaluation and testing.

When to seek care urgently rather than wait for a scheduled workup: sudden heavy or prolonged bleeding, severe pelvic pain, symptoms of a pituitary mass (new headaches, vision changes, unexpected milky nipple discharge), or a bone fracture with minimal trauma in a woman with known amenorrhea. These warrant prompt medical evaluation rather than routine follow-up.

Matching treatment to cause (general orientation, not a prescription)